Allogene Therapeutics (ALLO) Granted IND Clearance from FDA for ALLO-605
- Dow reaches all-time high on commodity surge; S&P, Nasdaq drop
- Dogecoin Sees 'Sell the News' Reaction to Musk's SNL Appearance, as 'Hustle' Comment is Weighed Against Launch 'To the Moon'
- Alphabet (GOOGL) and Facebook (FB) Downgraded to 'Neutral' at Citi as Decelerating Growth Is Not Bullish for Multiples
- Elliott Management has stake in Duke Energy (DUK) - WSJ
- Ethereum (ETH) Soars Above $4,000 to Print Fresh Record Highs
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Allogene Therapeutics, Inc. (NASDAQ: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer today announced that the U.S. Food & Drug Administration (FDA) has cleared an Investigational New Drug (IND) application to study ALLO-605 for the treatment of patients with relapsed or refractory multiple myeloma. ALLO-605 is part of the company’s multi-faceted strategy to develop an allogeneic CAR T therapy targeting BCMA for the treatment of multiple myeloma. The Phase I IGNITE trial will evaluate escalating doses of ALLO-605 beginning in mid-2021.
ALLO-605 is the Company’s first TurboCAR™ clinical candidate. TurboCAR is a proprietary, next generation platform technology based on a programmable cytokine signaling, designed to control T cell exhaustion, and improve T cell function and potency to reduce dosing requirement of AlloCAR T™ cells. These properties may enable CAR T therapy to succeed in more difficult to treat hematologic malignancies and solid tumors.
“Clearance of the ALLO-605 IND marks the beginning of the third stage of our three-pronged strategy targeting BCMA for relapsed/refractory multiple myeloma,” said Rafael Amado, M.D., Executive Vice President of Research & Development and Chief Medical Officer of Allogene. “We look forward to initiating the IGNITE trial and are excited to advance a new technology platform that has the potential to transform the field of engineered T cell therapy.”
As part of the Company’s anti-BCMA strategy, Allogene continues to enroll relapsed/refractory multiple myeloma patients in the Phase 1 UNIVERSAL study with the goal of optimizing dosing of ALLO-715 and ALLO-647. Allogene in collaboration with SpringWorks Therapeutics is also evaluating ALLO-715 in combination with the investigational gamma secretase inhibitor, nirogacestat, for the treatment of multiple myeloma.
About ALLO-605ALLO-605 is a next-generation AlloCAR T investigational therapy that targets the B-cell maturation antigen (BCMA) for the treatment of patients with relapsed/refractory multiple myeloma and other BCMA-positive malignancies. ALLO-605 incorporates Allogene’s proprietary TurboCAR technology, which allows for cytokine activation signaling to be engineered selectively into CAR T cells. Preclinical results with ALLO-605 were presented at the American Society of Hematology (ASH) annual meeting in December 2020.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Surgalign (SRGA) Submits Premarket Notification 510(k) of Its Digital Surgical Guidance System
- Vaxcyte (PCVX) Announces Publication of Preclinical Data Supporting the Potential of VAX-24 for the Prevention of Invasive Pneumococcal Disease
- UPDATE: NTSB Issues Preliminary Report on April 17 Texas Tesla (TSLA) Crash
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Related EntitiesTwitter, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!